caa a22 4500 445883057 CHVBK 20180317145550.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s10157-011-0438-9 doi (NATIONALLICENCE)springer-10.1007/s10157-011-0438-9 Treatment of metastatic renal cell carcinoma and renal pelvic cancer [Elektronische Daten] [Nozomu Tanji, Masayoshi Yokoyama] A better understanding of the molecular biology of renal cell carcinoma (RCC) and the emergence of molecular targeted drugs have revolutionized the treatment for patients with metastatic RCC (mRCC). Multi-targeted tyrosine kinase inhibitors (sorafenib and sunitinib) and mammalian target of rapamycin inhibitors (temsirolimus and everolimus) have recently shown superiority over interferon-α or placebo. However, while the molecular targeted drugs have demonstrated encouraging results, these drugs have also sometimes induced unexpected adverse events. Control of adverse events is important to obtain the maximum effectiveness and sustain quality of life for patients. Because renal pelvic cancer has many similarities in pathogenesis with urinary bladder cancer, the same chemotherapeutic regimen is often proposed for patients with metastatic renal pelvic cancer. Combined chemotherapy with gemcitabine and cisplatin is now widely considered to be first-line chemotherapy against these metastatic diseases; however, there are still unresolved problems with this treatment, including the limited survival benefit. To select new therapeutic modalities, a more profound understanding of the molecular biology of renal pelvic cancer is crucial. The purpose of this review is to summarize the current evidence supporting the role and activities of new chemotherapeutic agents and to reveal potential future directions in the management of mRCC and renal pelvic cancer. Japanese Society of Nephrology, 2011 Renal cell carcinoma nationallicence Molecular targeted drug nationallicence Renal pelvic cancer nationallicence Combination of gemcitabine and cisplatin nationallicence Tanji Nozomu Department of Urology, Ehime University Graduate School of Medicine, Shitsukawa, 791-0295, Toon, Ehime, Japan aut Yokoyama Masayoshi Department of Urology, Ehime University Graduate School of Medicine, Shitsukawa, 791-0295, Toon, Ehime, Japan aut Clinical and Experimental Nephrology Springer Japan 15/3(2011-06-01), 331-338 1342-1751 15:3<331 2011 15 10157 https://doi.org/10.1007/s10157-011-0438-9 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10157-011-0438-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tanji Nozomu Department of Urology, Ehime University Graduate School of Medicine, Shitsukawa, 791-0295, Toon, Ehime, Japan aut NATIONALLICENCE 700 1- Yokoyama Masayoshi Department of Urology, Ehime University Graduate School of Medicine, Shitsukawa, 791-0295, Toon, Ehime, Japan aut NATIONALLICENCE 773 0- Clinical and Experimental Nephrology Springer Japan 15/3(2011-06-01), 331-338 1342-1751 15:3<331 2011 15 10157 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer